Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807394 | 0.89 | L3MBTL1 (0.40) | KDM4CICAM1SELEMEN1KMT2A | |
| SCHEMBL4812134 | 0.89 | KDM4C (0.39) | KDM4CICAM1SELEADORA3MEN1 | |
| SCHEMBL12876153 | 0.88 | FFAR1 (0.38) | KDM4CICAM1SELEKDM4E | |
| SCHEMBL4807205 | 0.87 | PPARD (0.37) | ICAM1SELEMEN1KMT2AKDM4E | |
| SCHEMBL1197624 | 0.86 | MEN1 (0.41) | KDM4CMEN1KMT2A | |
| SCHEMBL5420567 | 0.81 | CDC7 (0.53) | ADORA3MEN1KMT2AKDM4E | |
| SCHEMBL4811874 | 0.78 | L3MBTL1 (0.40) | KDM4CICAM1SELEKDM4EPOLB | |
| SCHEMBL12876150 | 0.77 | FFAR1 (0.36) | KDM4CMEN1KMT2AKDM4E | |
| SCHEMBL3537630 | 0.77 | PPARD (0.36) | KDM4CICAM1SELEMEN1KMT2A | |
| SCHEMBL1198888 | 0.77 | GRIN1 (0.37) | KDM4CMEN1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449468-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-09-27 | — | — | US | disclosed |
| US-7229998-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-03-29 | — | — | US | disclosed |
| EP-1349843-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1349843-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002059098-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | PPARD, PPARG, PPARA | KDM4C 4603/4885ICAM1 4696/4885SELE 4138/4885 |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GPR119, PPARA, PPARG | KDM4C 4446/4885ICAM1 4508/4885SELE 3616/4885 |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | PPARA, PPARG, PPARD | KDM4C 4712/4885ICAM1 4474/4885SELE 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.